Combination of Mesothelin and CEA Significantly Improves the Differentiation between Malignant Pleural Mesothelioma, Benign Asbestos Disease, and Lung.

Slides:

Advertisements

Similar presentations

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,

Advertisements

Hippo Pathway Gene Mutations in Malignant Mesothelioma: Revealed by RNA and Targeted Exon Sequencing Akihiko Miyanaga, MD, PhD, Mari Masuda, PhD, Koji.

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages

A Hole in the Heart Journal of Thoracic Oncology

Pleurectomy/Decortication, Hyperthermic Pleural Lavage with Povidone-Iodine Followed by Adjuvant Chemotherapy in Patients with Malignant Pleural Mesothelioma

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung Sai-Hong.

Outcome for Patients with Malignant Pleural Mesothelioma Referred for Trimodality Therapy in Western Australia Arman Hasani, MBBS, FRACP, John M. Alvarez,

Prognostic Factors in the Treatment of Malignant Pleural Mesothelioma at a Large Tertiary Referral Center Raja M. Flores, MD, Maureen Zakowski, MD, Ennapadam.

Clinical Value of Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Differentiation of Malignant Mesothelioma from Asbestos-Related.

Epidemiology of Environmental Exposure and Malignant Mesothelioma

Early Detection of Lung Cancer by Molecular Markers in Endobronchial Epithelial-Lining Fluid Nicolas Kahn, MD, Michael Meister, PhD, Ralf Eberhardt,

Epidemiology of Environmental Exposure and Malignant Mesothelioma

Pleurectomy/Decortication, Hyperthermic Pleural Lavage with Povidone-Iodine Followed by Adjuvant Chemotherapy in Patients with Malignant Pleural Mesothelioma

Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG.

Incidence and Survival of Malignant Pleural Mesothelioma in Norway: A Population- Based Study of 1686 Cases Åslaug Helland, MD, PhD, Steinar Solberg,

Pleural Fluid Cytological Yield and Visceral Pleural Invasion in Patients with Epithelioid Malignant Pleural Mesothelioma Valentina Pinelli, MD, Sophie.

Prognostic factors and survival after complete resection of pulmonary metastases from colorectal carcinoma: Experiences in 167 patients Joachim Pfannschmidt,

Joachim Pfannschmidt, MD, Hans Hoffmann, MD, Hendrick Dienemann, MD

Folate Receptor–Positive Circulating Tumor Cell Detected by LT-PCR–Based Method as a Diagnostic Biomarker for Non–Small-Cell Lung Cancer Xiaoxia Chen,

Electronic Updates for JTO Readers

The pregnancy associated protein glycodelin as a follow-up biomarker in a male non- small cell lung cancer patient Marc A. Schneider, Nicolas C. Kahn,

Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,

John E. Pilling, FRCS (CTh), Michael E

An Unusual Presentation of Malignant Pleural Mesothelioma

Prognostic Impact of Malignant Pleural Effusion at Presentation in Patients with Metastatic Non–Small-Cell Lung Cancer Daniel Morgensztern, MD, Saiama.

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Frank Detterbeck, MD Journal of Thoracic Oncology

Frequency of Use and Predictors of Cancer-Directed Surgery in the Management of Malignant Pleural Mesothelioma in a Community-Based (Surveillance, Epidemiology,

Validation of the SHOX2/PTGER4 DNA Methylation Marker Panel for Plasma-Based Discrimination between Patients with Malignant and Nonmalignant Lung Disease

Diagnosis of Mediastinal Adenopathy—Real-Time Endobronchial Ultrasound Guided Needle Aspiration versus Mediastinoscopy Armin Ernst, MD, FCCP, Devanand.

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

Prospective Study on Functional Results After Lung-Sparing Radical Pleurectomy in the Management of Malignant Pleural Mesothelioma Servet Bölükbas, MD,

A Pragmatic Approach to the Diagnosis of Nodal Micrometastases in Early Stage Non- small Cell Lung Cancer Esther Herpel, MD, Thomas Muley, PhD, Thomas.

“The Best-Laid Plans … Often go Awry …”

A Hole in the Heart Journal of Thoracic Oncology

Perception of Lung Cancer among the General Population and Comparison with Other Cancers Julien Mazières, MD, PhD, Jean-Louis Pujol, MD, PhD, Nikos Kalampalikis,

A Case of Pleural Epithelioid Sarcoma of Proximal Type Presenting as Malignant Pleural Mesothelioma Gitte Anna Madsen, MD, Torben Riis Rasmussen, MD,

Onkar V. Khullar, MD, Yuan Liu, PhD, Theresa Gillespie, PhD, Kristin A

CCL2, Galectin-3, and SMRP Combination Improves the Diagnosis of Mesothelioma in Pleural Effusions Christophe Blanquart, PhD, Fabien Gueugnon, PhD, Jean-Michel.

Treatment of Malignant Pleural Mesothelioma with Carboplatin, Liposomized Doxorubicin, and Gemcitabine: A Phase II Study Gunnar Hillerdal, MD, PhD, Jens.

Mirror Mirror on the Wall, Who Is the Fairest of Them All

Combined Serum Mesothelin and Plasma Osteopontin Measurements in Malignant Pleural Mesothelioma Alfonso Cristaudo, MD, Alessandra Bonotti, PhD, Silvia.

A Simple Solution for Complicated Pleural Effusions

Nivolumab-Induced Granulomatous Inflammation of the Pleura

MTP13-01: Indications and limitations of bronchoscopy

Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease Hao-Xian Yang,

Prognostic Factors in the Treatment of Malignant Pleural Mesothelioma at a Large Tertiary Referral Center Raja M. Flores, MD, Maureen Zakowski, MD, Ennapadam.

The impact of lymph node station on survival in 348 patients with surgically resected malignant pleural mesothelioma: Implications for revision of the.

Clinical Significance of Serum Vascular Endothelial Growth Factor in Malignant Pleural Mesothelioma Akihiro Yasumitsu, MD, Chiharu Tabata, MD, PhD, Rie.

Conditional Survival of Malignant Thymoma Using National Population-Based Surveillance, Epidemiology, and End Results (SEER) Registry (1973–2011) Ellen.

Pleurectomy/Decortication is Superior to Extrapleural Pneumonectomy in the Multimodality Management of Patients with Malignant Pleural Mesothelioma Loïc.

Lung Volume Measurements as a Surrogate Marker for Patient Response in Malignant Pleural Mesothelioma Zacariah E. Labby, PhD, Samuel G. Armato, PhD,

T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)

Pulmonary Resection for Metastases from Colorectal Cancer

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

An Electrocautery Pleural Biopsy for the Diagnosis of Desmoplastic Malignant Mesothelioma During Semirigid Thoracoscopy Shinji Sasada, MD, Kunimitsu.

Genetic Changes in Squamous Cell Lung Cancer: A Review

European Lung Cancer Conference (ELCC) 2016 Organisation

A Pathological Complete Response in Malignant Pleural Mesothelioma after Combination Chemotherapy with Carboplatin and Pemetrexed Steven Chuan-Hao Kao,

Combined Evaluation of Postoperative Serum Levels of Carcinoembryonic Antigen Less than or Equal to 2.5 ng/ml and Absence of Vascular Invasion may Predict.

Pleural Metastases of Malignant Melanoma

Epidemiology of Thymoma and Associated Malignancies

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer James B. Yu, MD, Roy H. Decker, MD, PhD,

Cytokine Gene Therapy for Malignant Pleural Mesothelioma

Rogerio C. Lilenbaum, MD, John Cashy, PhD, Thomas A

Debby P. M. van den Bogaert, MD, Ellen M

A Review of First-Line Treatment for Small-cell Lung Cancer

Robert Comis, MD, The Passing of a “Lung Man”

Presentation transcript:

Combination of Mesothelin and CEA Significantly Improves the Differentiation between Malignant Pleural Mesothelioma, Benign Asbestos Disease, and Lung Cancer Thomas Muley, PhD, Hendrik Dienemann, MD, PhD, Felix JF Herth, MD, PhD, Michael Thomas, MD, PhD, Michael Meister, PhD, Joachim Schneider, MD, PhD Journal of Thoracic Oncology Volume 8, Issue 7, Pages 947-951 (July 2013) DOI: 10.1097/JTO.0b013e31828f696b Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Scatterplot of mesothelin versus CEA in the study population (both axes in logarithmic scale). CEA, carcinoembryonic antigen; MPM, malignant pleural mesothelioma. Journal of Thoracic Oncology 2013 8, 947-951DOI: (10.1097/JTO.0b013e31828f696b) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Boxplot of CEA, mesothelin, and the quotient mesothelin/CEA in the various study groups. The results of pairwise comparison (two–tailed Mann–Whitney U test) are given in the tables. CEA, carcinoembryonic antigen; LC, lung cancer; MPM, malignant pleural mesothelioma. Journal of Thoracic Oncology 2013 8, 947-951DOI: (10.1097/JTO.0b013e31828f696b) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Receiver operating chracteristic curves for the comparison of MPM versus lung cancer (left) and for MPM versus benign asbestos disease (right) for mesothelin alone, for CEA, and for the quotient mesothelin/CEA. MPM, malignant pleural mesothelioma; AUC, area under the curve. Journal of Thoracic Oncology 2013 8, 947-951DOI: (10.1097/JTO.0b013e31828f696b) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions